The effect of imatinib mesylate for newly diagnosed philadelphia chromosome-positive, chronic-phase myeloid leukemia in sub-saharan african patients: The experience of côte d'ivoire

Advances in Hematology

Volumn 2010, Issue , 2010, Pages

  Koffi, K G ^a   Nanho, D C ^a   N'Dathz, E ^a   Kouehion, P ^a   Dissieka, R ^a   Attia, A ^a   Mozard, K ^a   Tolo, A ^a   Boidy, K ^a   Meite N ^a   Ayemou, R ^a   Sekongo, M ^a   Tea, N ^a   Sanogo, I ^a  

^a Haematology National Teaching Hospital of Abidjan   (Côte d’Ivoire)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADOLESCENT; ADULT; AFRICA; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BONE PAIN; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COTE D'IVOIRE; DIARRHEA; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HUMAN; MALE; MUSCLE CRAMP; NAUSEA; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; RASH; SURVIVAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 77957861449     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2010/268921     Document Type: Article

References (25)

1. Rowley J. D., A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining Nature 1973 243 5405 290 293
2. Daley G. Q., Van Etten R. A., Baltimore D., Induction of chronic myelogenous leukemia in mice by the P210(bcr/abl) gene of the Philadelphia chromosome Science 1990 247 4944 824 830
3. O'Dwyer M. E., Mauro M. J., Druker B. J., Recent advancements in the treatment of chronic myelogenous leukemia Annual Review of Medicine 2002 53 369 381
4. Druker B. J., Talpaz M., Resta D. J., Peng B., Buchdunger E., Ford J. M., Lydon N. B., Kantarjian H., Capdeville R., Ohno-Jones S., Sawyers C. L., Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia New England Journal of Medicine 2001 344 14 1031 1037
5. Kantarjian H. M., Dixon D., Keating M. J., Talpaz M., Walters R. S., McCredie K. B., Freireich E. J., Characteristics of accelerated disease in chronic myelogenous leukemia Cancer 1988 61 7 1441 1446 (Pubitemid 18076421)
6. Sokal J. E., Baccarani M., Russo D., Tura S., Staging and prognosis in chronic myelogenous leukemia Seminars in Hematology 1988 25 1 49 61
7. Muheez A. D., Julius O. F., Oyekunle A. A., The use of Imatinib mesylate in Nigerians with chronic myeloid leukemia Cellular Therapy and Transplantation 2008 1 2 15
8. Boma P. O., Durosinmi M. A., Adediran I. A., Akinola N. O., Salawu L., Clinical and prognostic features of Nigerians with chronic myeloid leukemia The Nigerian postgraduate medical journal 2006 13 1 47 52
9. Okany C. C., Akinyanju O. O., Chronic leukaemia: an African experience Medical Oncology and Tumor Pharmacotherapy 1989 6 3 189 194
10. Fleming A. F., Menendez C., Parry E., Godfrey R., Mabey D., Gill G., Blood Principles of Medicine in Africa 2004 78 Cambridge, UK Cambridge University Press
11. Groves F. D., Linet M. S., Devesa S. S., Patterns of occurrence of the leukaemias European Journal of Cancer Part A 1995 31 6 941 949
12. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., Niederwieser D., Resta D., Capdeville R., Zoellner U., Talpaz M., Druker B., Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia New England Journal of Medicine 2002 346 9 645 652
13. Sokal J. E., Gomez G. A., Baccarani M., Tura S., Clarkson B. D., Cervantes F., Rozman C., Carbonell F., Anger B., Heimpel H., Nissen N. I., Robertson J. E., Prognostic significance of additional cytogenetic abnormalities at diagnosis of Philadelphia chromosome-positive chronic granulocytic leukemia Blood 1988 72 1 294 298
14. Kantarjian H. M., Smith T. L., McCredie K. B., Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival Blood 1985 66 6 1326 1335
15. Kantarjian H. M., Cortes J. E., O'Brien S., Giles F., Garcia-Manero G., Faderl S., Thomas D., Jeha S., Rios M. B., Letvak L., Bochinski K., Arlinghaus R., Talpaz M., Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses Blood 2003 101 1 97 100 (Pubitemid 36025893)
16. O'Brien S. G., Guilhot F., Larson R. A., Gathmann I., Baccarani M., Cervantes F., Cornelissen J. J., Fischer T., Hochhaus A., Hughes T., Lechner K., Nielsen J. L., Rousselot P., Reiffers J., Saglio G., Shepherd J., Simonsson B., Gratwohl A., Goldman J. M., Kantarjian H., Taylor K., Verhoef G., Bolton A. E., Capdeville R., Druker B. J., Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia New England Journal of Medicine 2003 348 11 994 1004 (Pubitemid 36302244)
17. Kantarjian H., Talpaz M., O'Brien S., Garcia-Manero G., Verstovsek S., Giles F., Rios M. B., Shan J., Letvak L., Thomas D., Faderl S., Ferrajoli A., Cortes J., High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia Blood 2004 103 8 2873 2878 (Pubitemid 38451654)
18. Rodriguez J., Cortes J., Smith T., O'Brien S., Rios M. B., Talpaz M., Kantarjian H., Determinants of prognosis in late chronic-phase chronic myelogenous leukemia Journal of Clinical Oncology 1998 16 12 3782 3787
19. Sacchi S., Kantarjian H. M., O'Brien S., Beran M., Koller C., Pierce S., Kornblau S., Estey E., Keating M. J., Talpaz M., Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia Leukemia 1997 11 10 1610 1616
20. Kantarjian H. M., Talpaz M., O'Brien S., Smith T. L., Giles F. J., Faderl S., Thomas D. A., Garcia-Manero G., Issa J.-P.J., Andreeff M., Kornblau S. M., Koller C., Beran M., Keating M., Rios M. B., Shan J., Resta D., Capdeville R., Hayes K., Albitar M., Freireich E. J., Cortes J. E., Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon- : follow-up results Clinical Cancer Research 2002 8 7 2177 2187
21. Deininger M. W. N., Druker B. J., Specific targeted therapy of chronic myelogenous leukemia with imatinib Pharmacological Reviews 2003 55 3 401 423
22. Gorre M. E., Mohammed M., Ellwood K., Hsu N., Paquette R., Nagesh Rao P., Sawyers C. L., Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 2001 293 5531 876 880
23. Hasford J., Pfirrmann M., Hehlmann R., Allan N. C., Baccarani M., Kluin-Nelemans J.C., Alimena G., Steegmann J. L., Ansari H., A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa Journal of the National Cancer Institute 1998 90 11 850 858
24. Sokal J. E., Cox E. B., Baccarani M., Prognostic discrimination in good-risk chronic granulocytic leukemia Blood 1984 63 4 789 799
25. Tolo-Diebkil A., Koffi K. G., Sawadogo G. D., Therapeutic Impact of interferon in chronic myelogenous leukemia Mali Medical 2010 25 1 22 27